Follikuláris limfóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 27
• CD20 14
• BTK 9
• BCL-2 5
• CD22 5
• MYC 3
• EZH2 2
• PD-1 3
• PI3K 0
• PD-L1 1
• TP53 0
• CD40 0
• CD47 0
• CXCR4 0
• EGFR 0
• HDAC 0
• ABL1 0
• AKT 0
• ALK 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD30 0
• CSF1R 1
• G6PD 0
• IL-1 0
• IL-15 0
• IL-17 0
• LAG-3 0
• MEK 0
• PPAR 0
• STAT3 0
• TFEB 0
• TIGIT 1
• TIM-3 0

12+ intézményből 12, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxemburg· EU contribution 216 240 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Making patient-derived tumor organoids a reliable cancer therapy testing platform (TUMORGPLAT)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 245 490 EUR· until 2029. dec.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in the Tissue Microenvironment

  Academisch Ziekenhuis Leiden· Leiden, Hollandia· EU contribution 296 296 EUR· until 2027. ápr.· 2 countries

3 of 3 running projects, newest first. Listed amounts together: 758,0 E EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

  NCT03789240· National Cancer Institute (NCI)· Forrás

• Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

  NCT04282018· BeiGene· Forrás

• A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Incyte Corporation· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Whole Genome Sequencing 1
• Flow Cytometry 2
• Immunohistochemistry 12
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 2
• Cohort Studies 6
• Genome-Wide Association Study 4

• Single-cell sequencing reveals dynamic immune features of paraneoplastic pemphigus in a patient with follicular lymphoma.

  Front Immunol, 2026. márc.

• Biomarkers Informed by Single-Cell and Spatial Transcriptomics-Biomarkers for Grade 3 Follicular Lymphoma.

  Mod Pathol, 2026. jan.

• [Uncovering the pathogenesis of malignant lymphoma by single-cell analysis].

  Rinsho Ketsueki, 2026. jan.

• scFFPE-ATAC enables high-throughput single cell chromatin accessibility profiling in formalin-fixed paraffin-embedded samples.

  Nat Commun, 2025. nov.

  Tobias Sjöblom

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.